Breast Cancer News and Research

Latest Breast Cancer News and Research

Study finds racial disparities in breast cancer care

Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

New antibody-drug compound halts growth of metastatic breast tumors

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

14 Dec 2009

Additional therapy and screening may be needed for patients with mucinous breast cancer

In a large review of breast cancer patients with mucinous carcinoma, researchers at The University of Texas M. D. Anderson Cancer Center have identified an association between this rare type of breast cancer long-associated with a favorable prognosis and multiple tumors undetected by mammography or ultrasound.

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

A new study finds many breast cancer patients - particularly African American women - do not receive recommended radiation treatments after undergoing a lumpectomy.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Findings from three studies using bioTheranostics' breast cancer molecular test reported

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test.

14 Dec 2009

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.

14 Dec 2009

Data from Phase 3 clinical evaluation of Lymphoseek presented

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that researchers who participated in the breast cancer arm of a Phase 3 clinical evaluation of Lymphoseek® presented data from their clinical experience at the International San Antonio Breast Cancer Symposium.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

In a study published online this week in the leading cancer journal, Journal of Clinical Oncology, Westchester Medical Center Physician Dr. Kutluk Oktay, MD, Director, Division of Reproductive Medicine & Infertility concluded that mutations in the BRCA1 gene (gene associated with early onset breast cancer) are associated with early diminishment of egg reserve.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

13 Dec 2009

Breast Cancer News and Research

Latest Breast Cancer News and Research

Study finds racial disparities in breast cancer care

New antibody-drug compound halts growth of metastatic breast tumors

Additional therapy and screening may be needed for patients with mucinous breast cancer

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Combination therapy improves overall survival in women with advanced breast cancer

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Genentech announces positive results from Phase II study of T-DM1

Texas researchers identify new detection method for circulating tumor cells

Findings from three studies using bioTheranostics' breast cancer molecular test reported

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

Data from Phase 3 clinical evaluation of Lymphoseek presented

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Breast Cancer News and Research

Latest Breast Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in